StockNews.com Begins Coverage on RedHill Biopharma (NASDAQ:RDHL)

Stock analysts at StockNews.com started coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

RedHill Biopharma Stock Down 9.4 %

RDHL stock opened at $3.85 on Tuesday. RedHill Biopharma has a fifty-two week low of $3.01 and a fifty-two week high of $20.27. The business has a 50-day moving average of $5.87 and a 200-day moving average of $15.06.

Institutional Trading of RedHill Biopharma

A hedge fund recently bought a new stake in RedHill Biopharma stock. GAMMA Investing LLC purchased a new stake in RedHill Biopharma Ltd. (NASDAQ:RDHL) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned about 0.40% of RedHill Biopharma at the end of the most recent quarter. 7.20% of the stock is currently owned by institutional investors and hedge funds.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.